# Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

> **NCT06215586** · PHASE2 · COMPLETED · sponsor: **Cardurion Pharmaceuticals, Inc.** · enrollment: 303 (actual)

## Conditions studied

- Heart Failure
- Heart Failure Preserved Ejection Fraction
- Cardiovascular Diseases
- Heart Diseases

## Interventions

- **DRUG:** Tovinontrine (CRD-750
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06215586
- **Lead sponsor:** Cardurion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-13
- **Primary completion:** 2025-09-02
- **Final completion:** 2025-09-02
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06215586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06215586, "Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06215586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*